Thymus Therapy

Infusio / Treatments / Thymus Therapy

Thymus Therapy


Symptom Relief 0
Better Immune Function 0
More Energy 0
Anti Aging 0

What is Thymus Therapy?

The thymus gland is the “control center” of the immune system and is located above the heart. Its role is to produce and ‘educate’ specific cells to combat immune threats. As we age, the thymus gland loses potency. The goal of Infusio’s thymus therapy is to return the cellular immune system to a balanced state with a series of thymus peptides injections. This process is thought to restore and improve the immune system, enabling new cells to target pathogens and cancerous cells. This therapy is an important – if not the most important – non-specific immunotherapy because of its ability to activate and balance the cellular immune system.

Why Thymus Therapy?

The thymus gland is located just behind the sternum on top of the heart. This gland is the center of our immune system. The function of the thymus is to produce and “educate” T-lymphocytes (T cells). These cells are critical to the adaptive immune system. The thymus changes its size and function during our life cycle. It is largest and most active in newborns, infants and in the years prior to adolescence. By the early teens, the thymus begins to shrink and thymus tissue is replaced by fatty tissue.

Due to the reduction of size of the thymus gland during our life cycle, the thymus-dependent immune response decreases the older we get. When we reach 50, only about 15% of the thymus gland still functions. This leads to a significant increase in infections, cancer, and autoimmune diseases, which increases as we get older. Thymus Therapy introduces the body to missing cell information and is thought to help restoring thymus function and strengthen the body’s natural ability to fend off disease.

It is critical that enough of the thymus hormones are present in the extract. These are Thymosin Alpha 1, Thymosin Beta 4 and Thymolin. Many thymus products contain only minimal amounts of these hormones. Infusio uses highly potent thymus extracts made in Germany under GMP guidelines.

Origins of Thymus Therapy

The method of whay we now call Thymus Therapy traces back to Dr. Elis Sandberg from Sweden, who was having promising results in treating chronic diseases and cancer as far back as 1938. He developed his own high-molecular extract called THX. By the 1980’s Sandberg had successfully treated more than 50,000 patients. In addition to the positive results of his treatment, many of his patients experienced significant anti-aging effects. This method has been used in Germany now for over 20 years.

Only in 1960 did the Australian Immunologist J. Miller discover the function of the thymus. Today we know that the thymus is the central organ of the body’s defenses. The white blood cells formed in bone marrow reach the thymus as immature lymphocytes. Only 10% of these cells are trained in the thymus and deemed fit for use in the body’s defenses. They are trained to monitor and patrol the body and to recognize foreign cells, such as bacteria, viruses or cancer cells as alien. These foreign cells are then attacked and destroyed.

Immune Cells and Their Roles

Thymus Therapy helps to restore the body’s immune cells and strengthens the immune system’s ability to fight disease.

Natural Killer Cells

These cells attack foreign cells and work together with the so-called cytotoxic cells to destroy them.

Helper Cells

These cells are involved in making antibodies. These activate natural killer cells and cytotoxic cells.

Memory Cells

These cells store information for the immune system, enabling it to distinguish between foreign cells and their own cells.

Supressor Cells

These ensure that not too many antibodies are formed and control the killer cells, preventing excessive immune reactions.

Who Can Benefit from Thymus Therapy?

Infusio treatment protocols are based on the comprehensive Five Steps to Health approach.  Thymus therapy is part of the Cell Therapy Program, Cancer Care Program and Lyme & Tick-Borne Disease Protocol as an immune modulation treatment. Thymus therapy can also be done as a stand-alone protocol or as a maintenance treatment.

Patients with one or more of the following symptoms may benefit from Thymus Therapy:

  • Allergies
  • Arthritis
  • Asthma
  • Autoimmune diseases
  • Blood pressure irregularities
  • Cancer
  • Chronic fatigue
  • Chronic gastrointestinal problems
  • Chronic infections
  • Chronic liver disease
  • Diabetes mellitus
  • Disturbances of the thyroid gland
  • Fibromyalgia
  • General loss of vitality
  • General signs of aging
  • Hormonal dysfunction
  • Immune support in AIDS sufferers
  • Impotence and sterility
  • Infertility
  • Insomnia
  • Lyme disease
  • Male andropause
  • Menopause
  • Mood disorders
  • Multiple sclerosis
  • Osteoporosis
  • Prostate enlargement
  • Poor healing of wounds and fractures
  • Rheumatism
  • Sexual dysfunction
  • Skin disorders
  • Sleep disorders
  • Symptoms of menopause
  • Tinnitus

Clinical Applications of Thymus Extracts

The cellular branch of immunity is responsible for vigilance against chronic viruses, fungi, yeast, and parasitic infections as well as neoplasms and aging. Thymus extracts have been used clinically in a variety of ways involving some of these conditions. They have been used orally and as injectables; by themselves and in combination with other therapeutics. Thymus extracts have been used to treat severe and chronic allergies involving the respiratory tract and skin as well as in severe acute and chronic infectious diseases. The extracts have also been shown to reduce post-surgical infections, decrease the damage of chemotherapy and radiation and have been used as adjuncts to mainstream therapy for treatment of neoplasms. The review of literature presented in the following summary is a survey of the conditions treated using thymus extracts and demonstrates the research completed to date using thymus extracts: Summary of Clinical Studies of the Use of Thymus Extracts

Thymus Therapy Frequently Asked Questions

What is the Thymus and What Does it Do?

What Side Effects Can I Expect?

Usually after the 3rd or 4th application patients may see a reddening occurring around the injection site. This can last a few days and is harmless. It is a sign that your immune system is being activated. It is not an allergic reaction. If the area is too itchy you can apply some Benadryl or Aloe Vera crème to calm the reaction. During the therapy you may experience tiredness and low-grade flu symptoms. These are common side effects of the immune modulation.


General Resources

Thymus (Wikipedia)

Additional References

  • Adambokov, DA, Litvinov VI, Mambetov KB, Koshmuratov AG, Sabyrebekova TS. Immunity of middle age and aged patients with tuberculosis and its changes during multimodality treatment by using T-activin. [Russian] Problemy Tuberkuleza. 1998, (5):46-8.
  • Acevedo HF, Campbell-Acevedo EA, Galyon JC, Buffo MJ and Hartsock RJ: In vivo expression of membrane-associated human chorionic gonadotrophin by cells isolated from cancerous human tissues. Proc Am Ass Cancer Res 34: 27, 1994.
  • Acevedo HF, Krichevsky A, Campbell-Acevedo EA, Galyon JC, Buffo MJ and Hartsock RJ: Expression of membrane- associated human chorionic gonadotrophin, its subunits, and fragments by cultured human cancer cells. Cancer 69: 1829- 1842, 1992.
  • Acevedo HF, Krichevsky A, Campbell-Acevedo EA, Galyon JC, Buffo MJ and Hartsock RJ: Flow cytometry method for the analysis of membrane-associated human chorionic gonado- trophin, its subunits, and fragments on human cancer cells. Cancer 69: 1818-1828, 1992.
  • Alba, E, Visentin L, Farina C, Wierdis T. Prevention of infection and improvement of cenesthesia with thymostimulin during chemotherapy following mastectomy. Minerva Ginecologica . 1991 Dec 43 (12): 585.
  • Allen L. Goldstein
    Thymic hormones and lymphokines: basic chemistry and clinical applications.
    New York, Plenum Press 1984.
  • Andolina M, Dobrinz MG, Meraviglia L, Agosti E, Cazzola P. Myelopoisis induction on human bone marrow precursor cells by a calf thymic derivative (Thymomodulin); in vitro comparison with exogenous CSF. Int J Immunother. 1987, 3: 139.
  • Antoniv VF, Kravchenko DV, Kravchenko AV, Matela II, Korotkova TV. Changes in systemic and local immunity in patients with acute and chronic purulent sinusitis in response to regional lymphotrophic immunostimulating therapy. [Russian] Vestnik Otorinolaringologii. 1998, (3):28-30.
  • Arizona Poison Control Center, Personal communication. Oct. 13, 1993.
  • Arsenijevic S, Zivznovic A, Jevremovic M, Ristic P, Kastratovic B. The effect of complete thymic extract on motility and progressive motility of spermatozoa in asthenozoospermia. [Cyrillic] Srpski Arhiv Za Celokupno Lekarstvo. 1996 Nov-Dec, 124 (11-12):287-91.
  • Badamchian M, Mora CA, Baumann CA, Paino JE, Goldstein AL. Biodistribution of symtnetic thymosin alpha 1 in the serum, urine and major organs of mice. International Journal of Immunopharmacology 1997 Feb, 19(2):59-66.
  • Bagnato A, Brovedani P, Comina P, Molinaro P, Scalzo C, Triolo VA, Milani G. Long-term treatment with thymomodulin reduces airway hyperresponsiveness to methacholine. Annals of Allergy 1989 May, 62(5):425.
  • Balch G, Izzo F, Chiao P, Klostergaard J, Curley SA. Activation of human Kupffer cells by thymostimulin (TP-1) to produce cytotoxicity against human hepatocellular cancer. Annals of Surgical Oncology. 1997 Mar, 4(2):149-55.
  • Banos V, Gomez J, Garcia A, Ruiz J, Alvarez R, Lorenzo M, Canteras M, Valdes M. Effectiveness of immunomodulating treatment (thymostimulin) in chronic obstructive pulmonary disease. Respiration. 1997, 64:220-3.
  • Bazhanov NM, Arion VI, Sysoeva OP, Krugliakova EP. Tactivin in the combined treatment of acute inflammatory diseases of the maxillofacial area [Russian] Stomatologiia. 1996, 75(2):31-3.
  • Beall G, Kruger S, Morales F, Imagawa D, Goldsmith JA, Fisher D, Steinberg J, Phair J, Whaling S, Bitran J. A double-blind, placebo-controlled trial of thymostimulin in symptomatic HIV-infected patients. AIDS. 1990 Jul, 4(7):679.
  • Bennett BK, Hickie IB, Vollmer-Conna US, Quigley B, Brennan CM, Wakefield D, Douglas MP, Hansen GR, Tahmindjis AJ, Lloyd AR. The relationship between fatigue, psychological and immunological variables in acute infectious illness. Australian & New Zealand Journal of Psychiatry. 1998 Apr, 32(2):180-6.
  • Berkesi J, Tsang P, and Roboz JP. The mechanism and modulation of immune dysfunction in AIDS associated syndromes. In: Gupta S (ed), AIDS Associated Syndromes; Plenum Press, New York. 1985, P141-150.
  • Berkow R and Fletcher AJ. The Merck Manual of Diagnosis and Therapy; fifteenth edition. Merck Research Laboratories, Rathway, NJ 1987, 317.
  • Bernstein L, Hanisch R, Sullivan-Halley J and Ross RK: Treatment with human chorionic gonadotrophin and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev 4: 437-440, 1995.
  • Bischof P and Klopper A: Proteins of the Placenta: Biochemistry, Biology and Clinical Application, Karger, Basel, 1985.
  • Born J, Lange T, Hansen K, Molle M, Fehm HL, Effects of sleep and circadian rhythm on human circulating immune cells. Journal of Immunology. 1997 May 1, 158(9): 4454-64.
  • Bortolotti F, Cadrobbi P, Crifvellaro C, Armigliato M, Demanzini A, Lepore L, Carra F, Realdi G. Effect of an orally administered thymic derivative, Thymodulin, in chronic type B hepatitis in children. Curr Ther Res. 1988, 43:67.
  • Boyum A, Wiik P, Gustavsson E, Veiby OP, Reseland J, Haugen AH, Opstad PK. The effect of strenuous exercise, calorie deficiency and sleep deprivation on white blood cells, plasma immunoglobulins and cytokines. Scandinavian Journal of Immunology. 1996 Feb, 43(2):228-35.
  • Brivio V, Perego M, Mauri E, Gramzio F, Brivio O, Gariboldi G, Urso G, Nespoli A. Variations in interleukin-2 and interleukin-6 due to surgical trauma in cancer patients. [Italian] Giornale de Chirurgia 1998 Oct, 19(10):377-80.
  • Bulava GV, Nikulina VP. Evaluation of the effectiveness of immunomodulators in the treatment of patients with postoperative suppurative-septic complications [Russian] Khirurgiia. 1996, (2):104-7.
  • Cabral GA, Dove Pettit DA. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease [Review] Journal of Neuroimmunology. 1998 Mar 15, 83(1-2):116-23.
  • Cachoua A, Green MD, Valentine F, Muggia FM. Phase I/II trial of thymostimulin in opportunistic infections of the acquired immune deficiency syndrome. Cancer Investigation. 1989, 7(3):225.
  • Cairns BA, Yamamoto H, Smith D, Ramadan FM, Meyer AA. Dehydroepiandrosterone fails to improve immunoglobulin synthesis and lymphocyte mitogenic response after burn injury. Journal of Burn Care & Rehabilitation. 1994 Nov-Dec, 15(6):509-14.
  • Cangemi V, Volpino P, D’Andrea N, Gentili S, Ippoliti F, Piat G. Thymostimulin effect on the immune response in neoplastic patients submitted to surgical treatment. Panminerva Medica 1993 Dec, 35(4):218-23.
  • Capelli O, Rovatti E, Gilioli F, Garuti GC, Lega M, DeMaria D, Covi M, Capitolo S, Fontana A, Pellegrino M. BAL modifications after antiblastic and immunomodulant therapy in lung cancer. Respiration. 1992, 59 (Suppl 1): 50.
  • Carco F, and Guazzotti. L’impeigo terapeutico della timostimolina in soggetti positiv al virus HIV ed affetti da lymphadenopathy syndrome. Recenti Progressi in Medicina 1993, 1984(11):756.
  • Carr DJ, Serou M. Exogenous and endogenous opioids as biological response modifiers. [Review] Immunopharmacology. 1995 Nov, 31(1):59-71.
  • Cassileth BR. Thymus therapy for cancer [editorial; comment]. European Journal of Cancer. 1997 Apr, 33(4):57-8.
  • Cavagni G, Piscopo E, Rigoli E, Iuliano P, Bertolini P, Cazzola P. Food allergy in children: an attempt to improve the effects of the elimination diet with an immunomodulating agent (thymomodulin). A double-blind clinical trial. Immunopharmacol. & Immunotoxicol. 1989, 11(1):131.
  • Cazzola P, Mazzanti P, Bossi G. In vivo modulating effect of a calf thymus acid lysate on human T lymphocyte subsets and CD4+/CD8+ ratio in the course of different diseases. Therapeutic Research. 1987 Dec. 42(6).
  • Chung-Kuo Yao Li Hsueh Pao. Effect of thymic factor G on lipid peroxide, glutathione, and membrane fluidity in liver of aged rats. Acta Pharmacologica Sinica. 1993, 14(4):382-4.
  • Ciconi E, Capoluongo R, Balduzzi GF, Balzaretti F, Orecchia C. Perioperative treatment with thymostimuin in patients with stomach and colorectal neoplasms. Our experience with 114 cases. Minerva Chirurgica. 1992 May 31, 47(10):939.
  • Cohen MH, Chretien PB, Ihde DC, Fossieck Jr BE, Makuch R, Bunn Jr PA, Johnston AV, Shackney SE, Matthews MJ, Lipson SD, Kenady DE, Minna JD. Thymosin fraction V and intensive combination chemotherapy. JAMA. 1979 Apr. 27, 241(17).
  • Cybulski L and Turowski G. The effects of TFX on surgical therapy. Clinical considerations based on 14 years of observations. In: Chyrek-Borrowska S. (ed), Immunomodulation. Immunological Society, Bialowieza. 1987; 42.
  • Czaplicki J and Blonska B. Do active substances of the thymus influence the processes of aging? I. Effects of treatment with embryonal and early fetal thymic calf extract (ETCE) on some organs of grown-up young mice. Acta Medica Polona. 1989, 30 (1-2):59-75.
  • Czapliki J, Blonska B, Klementys A, Machniak M, Pesic MC, Brandys B, Grzybek H, Czarneck J. Do active substances of thymus influence the processes of aging? II. Liver morphology in aging mice treated with embryonyl and early fetal thymic calf extracts (ETCE) and mature calf thymic extracts (Thymex L and TFX). Thymus. 1990, 15(4):249-55.
  • Dabrowski MP and Dabrowski-Bernstein BK. Immunoregulatory Role of Thymus. CRC Press 1990, P97-127.
  • Dabrowski MP, Dabrowski-Bernszteir BK, Brosko WJ, Babiuch L, Kassur B. Immunotherapy of patients with chronic virus hepatitis. I. Maturation of human t-lymphocytes under influence of calf thymic hormone. Clin Immun Immunopath. 1980, 16:297.
  • Davies, EG and Levinsky RJ. Treatment of cell mediated immunodeficiency with calf thymic hormone (T.P.I.) Periatr Res. 1982, 16:573.
  • Daynes RA, Araneo BA, Hennebold J, Enioutina E, Mu HH. Steroids as regulators of the mammalian immune response [Review] Journal of Investigative Dermatology. 1995 Jul, 105 (1 Suppl): 14S-19S.
  • De Serdio JL, Villar A, Alvarez IE, Gil-Cubelo JA, Suner M, Hernandez R, Lopez-Aguado D. The effects of thymostimulin in a protocol or concurrent hyperfractionated carboplatin and irradiation. [Spanish] Acta Otorrinolaringoglica Espanola. 1997 Aug-Sep, 48(6):487-92.
  • DeWall EJ, Van Der Laan JW, Van Loveren H. Effects of prolonged exposure to morphine and methadone on in vivo parameters of immune function in rats. Toxicology. 1998 Aug 21, 129(2-3):201-10.
  • Di Francesco P, Pica F, Croce C, Favalli C, Tubaro E, Garaci E. Effect of acute or daily cocaine administration on cellular immune response and virus infection in mice. Natural Immunity & Cell Growth Regulation. 1990, 9(6):397-405.
  • Dieter E. Hager (Hrsg.)
    Thymusfaktoren, Thymuspräparate. Biologische Eigenschaften und klinische Aspekte
    Verlag Urban & Fischer, 1987.
  • Drews J. The experimental and clinical use of immune modulating drugs in the prophylaxis and treatment of infections. Infection. 1984, 12:157.
  • Driianskaia VE. The clinico-immunological effects of immunotherapy in patients with acute pyelonephritis. [Russian] Likarska Sprava. 1997 Jul-Aug, (4):89-92.
  • Drobyshev Viu, Volozhin AI, Agapov VS, Sashkina TI. Indications for the use of t-activin in the combined treatment of phlegmons of the maxillofacial area. [Russian] Stomatologiia. 1996 75(4):27-30.
  • Drozdova TS, Makhonova LA, Maiakova SA, Tabagari DZ. Immunologic correction using thymus gland preparation (t-activin) in the programmed treatment of patients with non-lymphoid leukemia. Gematologiia i Transfuziologiia. 1990 Jan, 35(1):14.
  • Dworniak D, Tchorzewski H, Pokoca L, Tkacz B, Drobnik S, Baj Z, Luciak M. Treatment with thymic extract TFX for chronic active hepatitis B. Archivum Immunologiae et Therapae Experimentalis. 1991, 39(5-6):537.
  • Ernst E. Thymus therapy for cancer? A criteria-based, systematic review. [Review]. European Journal of Cancer. 1997 Apr, 33(4):531-5
  • Erwin Zoch (Hrsg.)
    Thymic factors and their influence on BRM CSF, international symposion, European Academy, Nonnweiler 31.8. – 2.9.1990,
    Fellbach bei Stuttgart, Biosymposia, 1991, 103 S.
  • Erwin Zoch u.a.
    Thymus, Zentrale der Immunität und endokrines Steuerungsorgan
    Karl F. Haug Verlag, 2. Auflage 1987, 138 S.
  • F. Aiuti
    Thymus, thymic hormones and T lymphocytes
    London [u.a.]. Acad. Press. 1980. 9, 445 S.. Serono Foundation, Symposia. Proceedings; 38.
  • Fabris N. A neuroendocrine-immune theory of aging. Intern J Neuroscience. 1990, 51:373-5.
  • Fagiolo U, Amadori A, Biselli R, Paganelli R, Nisini R, Cozzi E, Zamarchi R, D’Amelio R. Quantitative and qualitative analysis of anti-tetanus taxoid antibody response in the elderly. Humoral immune response enhancement by thymostimulin. Vaccine. 1993 Oct, 11(13):1336-40.
  • Faunce DE, Gregory MS, Kovacs EJ. Effects of acute ethanol exposure on cellular immune responses in a murine model of thermal injury. Journal of Leukocyte Biology. 1997 Dec, 62(6):733-40.
  • Federico M, Gobbi PG, Moretti G, Avanzini P, Di Renzo N, Cavanna L, Ascari E, Silingardi V. Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. American Journal of Clinical Oncology. 1995,18(1):8-14.
  • Fietta A, Mangiarotti P, Gialdroni Grassi G. Chemotherapeutic agents: aspects of their activity on natural mechanisms of defense against infections. International Journal of Clinical Pharmacology, Therapy, & Toxicology. 1983 Jul, 21(7):325-38.
  • Fiocchi A, Borella E, Riva E, Arensi D, Travaglini P, Cazzola P, Giovannini M. A double-blind clinical trial for the evaluation of the therapeutical effectiveness of a calf thymus derivative (Thymomodulin) in children with recurrent respiratory infections. Thymus. 1986, 8:331-339.
  • Fiocchi A, Grasso U, Rottoli A, Travaglini P, Mazzanti P, Cazzola P, Giovannini M. A double-blind clinical trial on the effectiveness of a thymic derivative (thymodulin) in the treatment of children with atopic dermatitis. Int J Immunother. 1987, 3:279.
  • Fischbach, Frances. The Manual of Laboratory and Diagnostic Tests, 5th edition. Lippincott, New York, 1996, p613.
  • Frolov VM, Peresadin NA, Ershova IB, Demenkov VR, Miakina AV. The immunomodulating action of vilozen and splenin in angina patients against a background of chronic bronchitis. Vrachebnoe Delo. 1992 Aug, (8):79.
  • Garaschchenko TI, Markova TP, Chuvirov DG. Immunological indicators in children with laryngeal papillomatosis and possible ways of immunocorrection. [Russian] Vestnik Otorinolaringologii. 1996 Jul-Aug, (4):15-8.
  • Genova R, Guerra A. Thymodulin in management of food allergy in children. Int J Tiss Reac. 1986, 8:239.
  • Ghanta VK, Hiramoto NA, and Hiramoto RN. Thymic peptides as anti-aging drugs: effect of thymic hormones on immunity and life span. Intern. J. Neuroscience. 1990, 51:371-372.
  • Gieldanowski J. Immunomodulators-Thymus factors X (TFX) and levamisole in immune reactions and inflammatory processes. Arch Immun Ther Exp. 1981, 29:121.
  • Gilman, SC, Lewis AJ. Immuno-pharmacological approaches to drug development. In Williams M, and Malick JB (eds). Drug Discovery and Development. The Humana Press, Clifton, NJ, 1987:p227.
  • Griffith HW. Complete Guide to Medical Tests. Fisher Books, Tucson, AZ 1988: 228.
  • Grigor’ev MA, Mikhailenko AA, Mel’kova TP. Stage-by-stage complex immunologic correction in patients with bronchial asthma living in a large industrial and power plant region. Gigiena Truda i Professionalnye Zabolevaniia. 1989, (4):25.
  • Grismondi GL, Marini A, Scivoli L, Rigoni I. Human fibroblast interferon therapy alone and human fibroblast interferon combined with thymostimulin in genital papillomavirus infection associated with cervical intraepithelial neoplasia. Minerva Ginecologica. 1991, Dec: 43(12):581.
  • Guielbert L, Robertson SA and Wegmann TG: The trophoblast as an integral component of a macrophage-cytokine network. Immunol Cell Biol 71: 49-57, 1993.
  • Guliamov N, and Kriuchkov MI. The correction of disorders in the cytoenzymatic status of the immunocytes in Shigella infection by using taktivin. Terapevti-cheskii Arkhiv. 1991,63(11):27.
  • Günter Neumeyer
    Thymuspeptide zur Behandlung chronischer und maligner Erkrankungen, Karl F. Haug Verlag: Heidelberg 1996, EUR 29,95.
  • H. R. Maurer, A. L. Goldstein, E. D. Hager (Hrsg.)
    Thymic Peptides in Preclinical and Clinical Medicine – An Update
    München (u.a.), Zuckschwerdt Verlag, 1997, 188 S.
  • Hadden JW, Hadden EM. Therapy of secondary T-cell immunodeficiencies with biological substances and drugs. Medical Oncology & Tumor Pharmacotherapy. 1989, 6(1):11.
  • Hadden JW. Thymic endocrinology. Int J Immunopharm. 1992, 14(3):345-52.
  • Harper JI, Mason UA, White TR, Staughton RC, Hobbs JR. A double-blind placebo-controlled study of thymostimulin (TP-1) for the treatment of atopic eczema. British Journal of Dermatology. 1991 Oct, 125(4):368.
  • Harrower, Henry. Practical Endocrinology. Pioneer Printing Co., Glendale, CA 1932; 193.
  • Heidi G. Das Karzinoembryonale Antigen (CEA), In Bedeutsames Tumor Assoziertes Antigen des Menschen. Gesundheitswesen. 1973, 19:28.
  • Herman Friedman
    Thymus factors in immunity
    Conference, Academy of Science 3.-5.4.1974, New York, 547 S.
  • High KP, Handschumacher RE. Immunity, microbial pathogenesis, and immunophilins: finding the keys, now where are the locks? [Review] Infectious Agents & Disease. 1992 Jun, 1(3):121-35.
  • Iaffaioli RV, Frasci G, Tortora F, Ciardiello F, Nuzzo F, Scala R, Pacelli R, Bianco AR. Effect of thymic extract thymostimulin on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer. Thymus. 1988, 12:69-75.
  • Ianiushina VV. The use of T-activin in the intensive therapy of the postoperative period in gestosis patients. Anesteziologiia I Reanimatologiia. 1992 Jul-Aug, (4):42.
  • Ignat’eva EV, Chesnokova VM, Ivanova LN. Influence of thymosin (fraction 5) and tactivin on the function of the adrenal cortex in mice. Neuroscience & Behavioral Physiology. 1991 Nov-Dec, 21(6):536-9.
  • Irwin M, McClintick J, Costlow C, Fortner M, White J, Gillin JC. Partial night sleep deprivation reduces natural killer and cellular immune responses in humans. FASEB Journal. 1996 Apr, 10(5):643-53.
  • Kaliuzhnaia LD, Boiko MG, Stychinskaia LP, Babukhadiia NV. Experience in treating atopic dermatitis in children with vilozen. Vrachebnoe Delo. 1989 Jan, (1):90.
  • Karachunskii MA, Gergert VI, Iakovleva OB. Specific features of cellular immunity of pulmonary tuberculosis in patients with diabetes mellitus. [Russian] Problemy Tuberkuleza. 1997, (6):59-60.
  • Kartasheva VI, Tarasova LR, Zairat’iants OV, Belokrinitskii DV. T-activin in multimodal treatment of systemic lupus erythematosis in children. Pediatriia. 1991, (3):47.
  • Kasenov KU, Sundetov ZhS. Atmospheric fronts and the cellular and humoral immunity indices of healthy people. [Russian]. Fiziologiia Cheloveka. 1984 May-June, 10(3): 480-2.
  • Kerrebijin JD, Simons PJ, Balm AJ, Tas M, Knegt PP, deVries N, Tan IB, Drexhage HA, Balm AJ. The effects of thymostimulin on immunological function in patients with head and neck cancer. Clinical Otolaryngology & Allied Sciences. 1996 Oct, 21(5):455-62.
  • Kicka W, Juszcyk J, Ademik J, Orzynski R. Thymic factor X (TFX) in the treatment of acute and chronic active hepatitis type B. In IX International Congress of Infectious and Parasitic Diseases. (Munich) 1986.
  • Klein JL, Hamel E, Tayot JL and Yamasaki H: Growth suppression of tranformed cells by a human placental extract not related to transforming growth factor-beta. J Cancer Res Clin Oncol 117: 192-196, 1991.
  • Klein JL, Hamel E, Tayot JL and Yamasaki H: Growth suppression of tranformed cells by a human placental extract not related to transforming growth factor-beta. J Cancer Res Clin Oncol 117: 192-196, 1991.
  • Klein TW, Friedman H, Specter S. Marijuana, immunity and infection [Review] Journal of Neuroimmunology. 1998 Mar 15, 83(1-2):102-15.
  • Kogosova LS, Kovalenko NN, Strafun OV, Markov AE. The effect of vilozen on the immune status of bronchial asthma patients. Vrachebnoe Delo. 1990 Oct., (10):48.
  • Kohnlein HE, Neuwirth R, Lemperle G, Horterer H, Knorr J, Ritter R, Stickel E. The effect of weather on defense mechanism and mortality. [German]. Medizinische Welt. 1973 Apr. 27, 24(17):661-6.
  • Kojima K, Kanzaki H, Hatayama H, Fujimoto M, Narukawa S, Higuchi T, Kaneko Y, Mori T and Fujita J: Expression of leukaemia inhibitory factor (LIF) receptor in human placenta: a possible role for LIF in the growth and differentiation of tropho- blasts. Hum Reprod 10: 1907-1911, 1995.
  • Komarov FI, Rapoport SI, Kharaian LV. Seasonal rhythms in diseases of the internal organs. [Russian review]. Sovetskaia Meditsina. 1985, (5):80-4.
  • Kouttab NM, Prada M, Cazzola P. Thymomodulin: biological properties and clinical applications. Medical Oncology & Tumor Pharmacotherapy. 1989, 6(1):5.
  • Krutmann J. Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapy. Journal of Photochemistry & Photobiology. 1998 Jul 10, 44(2):159-64.
  • Lai N, Lavosi V, Pinna S, Salis G, Colombo E, Vargiu P. Postoperative infections: the use of thymostimulin (TP1) in patient at risk. Giornale di Chirurgia. 1992, 13(6-7):337.
  • Lasisz B, Zdrojewicz Z, Dul W, Strychalski J. Clinical trial of the treatment of rheumatoid arthritis with TFX (thumus factor X). Wiadomosci Lekarskie. 1990 Sep 1-15, 43(17-18):870.
  • Liberati Am, Ballatori E, Fizzotti M, Schippa M, Cini L, Cinieri S, Proietti MG, Di Marzio R, Senatore M, Grignani F. A randomized trial to evaluate the immuno-restorative properties of thymostimulin in patients with Hodgin’s disease in complete remission. Cancer Immunology Immunotherapy. 1988, 26:87-93.
  • Lieber MR, Warner-Lambert/Parke-Davis Lecture. Pathological and physiological double-strand breaks: roles in cancer, aging, and the immune system [Review] American Journal of Pathology. 1998 Nov, 153(5):1323-32.
  • Lunardi-Iskandar Y, Bryant JL, Zeman RA, Lam VH, Samaniego F, Besnier JM, Hermans P, Thierry AR, Gill P and Gallo RC: Tumorigenesis and metastasis of neoplastic Kaposi’s sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 375: 64-68, 1995.
  • M.C. Pesic (Hrsg.)
    Thymuspeptide, Thymusenzyme, Thymushormone in Forschung und Therapie
    Bad Harzburg, Thymus, Medizinischer Fachverlag, 1992, 258 S..
  • Macchiarini P, Danesi R, Del Tacca M, Angeletti CA. Effects of thymostimulin on chemotherapy-induced toxicity and long-term survival in small cell lung cancer patients. Anticancer Research. 1989, 9:193-6.
  • Makhonova LA, Susuleva NA, Il’iashenko VV, Poliakov VE. Treatment of lymphogranulomatosis in children. Pediatriia. 1991, (11):98.
  • Mantovani G, Proto E., Lai P, Turnu E, Sulis G, Puxeddu P, Del Giacco. Controlled trial of thymostimulin treatment of patients with primary carcinoma of the larynx resected surgically: Immunological and clinical evaluation and therapeutic prospects. Recenti Progressi In Medicine. 1992 May, 83(5):303.
  • Marcos C, Quirce S, Compaired JA, Lazaro M, Igea JM, Guesta J, Losada E. Severe anaphylactic reaction to thymostimulin. Allergy. 1991, 46:235-37.
  • Marjanska-Radziszewska J, Biez-Ciecialowa M, Szmigiel Z, Skotnicki AB. Application of thymic extract in patients suffering from Hodgkin’s disease. In: XI Congress of the Polish Heamatological Society Abstracts. Gdansk. 1975: 118.
  • Marquez MG, Pacheco G, Roux ME. IgA B and T cells in the intestinal villi of immunodeficient rats orally treated with thymomodulin. Acta Physiologica, Pharmacologica et Therapeutica Latinoamericana. 1998, 48(2):89-92.
  • Martelli MF, Velardi A, Rambotti P, Cernetti C, Bertotto A, Spinozzi F, Bracagia M, Falini B, Davis S. The in vivo effect of a thymic factor (thymostimulin) on immunologic parameters of patients with untreated Hodgkin’s disease. Cancer. 1982, 50:490-497.
  • Masihi, KN, Lange W, Lotzova E. Highlights of the International Symposium on Immunomodulators and nonspecific defense against Microbial infections. Nat Immun Cell Growth Regul. 1987,6:213.
  • Matusiewicz R, Wasniewski J, Kawalczyk M, Lebiedowski K, Czajkowski M. The effect of TFX-Polfa on peripheral blood granulocyte migration and phagocytize ability in patients receiving steroid therapy. In Chyrek-Borowska S. Immunomodulation. Bialoweiza, 1987: 47.
  • McCallister-Sistilli CG, Caggiula AR, Knopf S, Rose CA, Miller AL, Donny EC. The effects of nicotine on the immune system. [Review] Psychoneuroendocrinology. 1998 Feb, 23(2):175-87.
  • Meert KL, Long M, Kaplan J, Sarnaik AP. Alterations in immune function following head injury in children. Critical Care Medicine. 1995 May, 23(5):822-8.
  • Meneses G, Delgado MA, Perez-Machado MA, Prieto A, Alonso R, Carrion F, Lanzos, E, Alvarez-Mon M. Thymostimulin increases natural cytotoxic activity in patients with breast cancer. International Journal of Immunopharmacology. 1997 Apr, 19(4):187-93.
  • Miric M, Vasiljevic J, Bojic M, Popovic Z, Keserovic N, Peic M. Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results. Heart. 1996 Jun, 75(6):596-601.
  • Molloy RG, Nestor M, Collins KH, Holzheimer RG, Mannick JA, Rodrick ML. The humoral immune response after thermal injury: an experimental model. Surgery. 1994 Mar, 115(3):341-8.
  • Molto LM, Carballido JA, Manzano L, Olivier C, Lapuerta M, Alvarez-Mon M. Thymostimulin enhances the natural cytotoxic activity of patients with transitional cell carcinoma of the bladder. International Journal of Immuno-pharmacology. 1993. 15(3):335-41.
  • Mukherjee K and Das S: Human chorionic gonadotrophin, as a growth stimulant of murine tumour cells. IRCS Med Sci 12: 1101-1102, 1984.
  • Mustacchi G, Pavesi L, Milani S, Iaffaioli V, Caraco A, Comella G, Contu A, Farris A, Attado-Parinello G, Narcisi M, Brema F, Beni A, Bumma C. High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer: results of a randomized multicenter clinical trial. Anti-cancer Research. 1994, 14:617-20.
  • N. A. Byrom
    Thymic factor therapy
    New York, Raven Press, 1984.
  • Naglucksay S, Vedres I, Lelkes M, Madi-Szabo L, Palfi I. Immunological side effects of some long term taking medicaments. ActaBio-Medica de l’Ateneo Parmense. 1992, 63(1-2):125-31.
  • Navarro-Zorraquino M, Guemes A, Lozano R, Larrad L, Pastor C, Soria J, Morandiera J, Salinas JC. Role of thymostimulin in activating rejection in an experimental small bowel allograft. Transplantation Proceedings. 1996 Oct, 28(5):2479-81.
  • Negri, L, Calabrese F, Correggia F, Miozzo S, Giacomasso S. Chemotherapy and thymostimulin in the treatment of advanced-stage breast neoplasms. Minerva Medica. 1992, May 83(5):283.
  • Nezu R, Nakahara K. Role of malnutrition on immunity. [Japanese] Nippon Rinsho-Japanese Journal of Clinical Medicine. 1994 Feb, 52(2):410-4.
  • Novick DM, Ochshorn M, Kreek MJ. In vivo and in vitro studies of opiates and cellular immunity in narcotic addicts. [Review] Advances in Experimental Medicine & Biology. 1991, 288:159-70.
  • Odds FC, Pathogenesis of Candida infections. [Review] Journal of American Academy of Dermatology. 1994, 31(3 pt. 2):S2-5.
  • Oliunin IuA, Balabanova RM. Combined immunomodulating therapy in rheumatoid arthritis [Russian] Terapevticheskii Arkhiv. 1996, 68(5):13-6.
  • Pal’chun VT, Kriukov AL, Ogorodnikov DS, Uzdennikov AA, Kunel’skaia NL. On post-op strategies in surgically treated forms of ethmoid sinusitis [Russian] Vestnik Otorinolaringologii. 1998, (5):21-31.
  • Palmisano L. Thymostimulin treatment in AIDS related complex. Clin Immunol Immunopathol. 1988, 47:253.
  • Pandolfi F, Quinti I, Montella F, Voci MC, Schipani A, Guiseppe U, Aiuti F. T-dependent immunity in aged humans. II Clinical and immunological evaluation after three months of administering a thymic extract. Thymus. 1983, 5:235-40.
  • Park HM. The recovery of T cell blast formation in patients with gastrointestinal malignancy by calf thymus components. J Catholic Med College Korea. 1984, 37:1.
  • Pavesi L. Fluorourcil (F), with and without high-dose folinic acid (HDFA) plus Epirubicin (E) and Cyclophosphamide (C): FEC versus HDFA-FEC plus or minus Thymostimulin (TS) in metastatic breast cancer: results of a multicenter study. European Journal of Cancer. 1993, 29A:277(401).
  • PecoraR, Cherubini V, Cardinale G, Bartolotta E. Circadian variability of IgE in children: effects of a thymic hormone (thymomodulin). Pediatria Medica E Chirurgica. 1991 May-Jun, 13(3):277.
  • Periti P, Mini E. Immunomodulation by cancer chemotherapeutic agents. [Review] Chemioterapia. 1987 Dec, 6(6):399-402.
  • Periti P, Stringa G, Donati L, Mazzei T, Mini E, Novelli A. Teicoplanin—its role as systemic therapy of burn infections and as prophylaxis for orthopaedic surgery. Antimicrobial Prophylasis in Orthopaedic Surgery and Burns. European Journal of Surgery-Supplement. 1992, (567):3.
  • Periti P, Tonelli F, Mazzei T, Ficari F. Antimicrobial chemoimmunoprohylaxis in colorectal surgery with cefotetan and thymostimulin: prospective, controlled multicenter study. Study Group on Antimicrobial Prophylaxis in Abdominal Surgery. Journal of Chemotherapy. 1993 Feb, 5(1):37.
  • Perotti F, Landi G, Primatesta F, Colombo A, David PG, Castellaro E, Baraldi U. Thymostimulin immunoprophylaxis in elective abdominal surgery. Minerva Chirugica. 1992, Jun 30, 47(12):1091.
  • Poli G, Secchi C, Bonizzi L, Guttinger M. Stimulation of the antibody response after treatment with thymomodulin in mice immunodepressed with cyclophosphamide and in aging mice. Int J Tiss Reac. 1986, 8:231.
  • Quattrocchi KB, Miller CH, Wagner FC Jr, DeNardo SJ, DeNardo GL, Ovodov K, Frank EH. Cell-mediated immunity in severely head-injured patients: the role of suppressor lymphocytes and serum factors. Journal of Neurosurgery. 77(5):694-9 Nov.
  • Radchenko VG, Mitrofanova T, Serebriakova VI, Vinogradova GL. The efficacy of immunomodulating preparations in treating patients with chronic cholestatic liver diseases. Vrachebnoe Delo. 1992 Nov-Dec, (11-12):38.
  • Radomska G, Jankowski A, Prusek W. Immunomodulation in children with recurrent infections of respiratory tract. In: Chyrek-Borowska S (ed), Immunomodulation. Polish Immunological Society, Bailowieza, 1987, p. 46.
  • Raymond RS, Fallon MD, Abrams GA. Oral thymic extract for chronic hepatitis C in patients previously treated with interferon. A randomized, double-blind, placebo controlled trial. Annals of Internal Medicine. 1998 Nov 15, 129(1):797-800.
  • Reinke AHM. Cancer Follow-up: Immunotherapy has proved successful. Arztiche Praxis. Die Zeitung des Artztes in Kninik und Praxis. 1985, June 4, XXXVII (issue 45):2098.
  • Romanov VA, Borodin AG, Krylov VL. The use of taktivin for modulating the functional activity of the neutrophilic granulocytes in patients with systemic lupus erythematosus. Terapevticheskii Arkhiv. 1992, 64(5): 65.
  • Rosen FR, Steiner LA, Unanue ER. Dictionary of Immunology, Stockton Press, 1989; 50.
  • Rosenthal GJ, Germolec DR, Lamm KR, Ackerman MF, Luster MI. Comparative effects on the immune system of methotrexate and trimetrextate. International Journal of Immunopharmacology. 1987, 9)):793-901.
  • Rosenthal GJ, Weigand GW, Germolec DR, Glank JA, Luster MI. Suppression of B cell function by methtrexate and trimetrexate. Evidence for inhibition of purine biosynthesis as a major mechanism of action. Journal of Immunology. 1988 Jul 15, 141(2):410-6.
  • Rouveix B. Opiates and immune function. Consequences on infectious diseases with special reference to AIDS. [Review] Therapie. 1992 Nov, 47(6):503-12.
  • Roy S, Loh HH. Effects of opioids on the immune system. [Review] Neurochemical Research. 1996 Nov, 21(11):1375-86.
  • Russo IH and Russo J: Role of hGC and inhibin in breast cancer. Int J Oncol 4: 297-306, 1994.
  • Russo IH, Koszalka MS and Russo J: Protective effect of chorionic gonadotrophin on DMBA-induced mammary carcinogenesis. Br J Cancer 64: 481-484, 1990.
  • Sacks GS, Brown RO, Teague D, Dickerson RN, Tolley EA, Kudsk KA. Early nutrition support modifies immune function in patients sustaining severe head injury. Journal of Parenteral & Internal Nutrition. 1995 Sep-Oct, 19(5):387-92.
  • Samanci A, Yi Q, Fagerberg J, Strigard K, Smith G, Ruden U, Wahren B, Mellstedt H. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunology, Immunotherapy. 1998 Nov, 47(3):131-42.
  • Samsygin SA, Dolgina EN, Arion VYa, Romanova LA, Shchevochkina GI, Ovchinnikova EA. The effect of using T-activin in the therapy of the newborn with suppurative surgical infection. Journal of Hygiene, Epidemiology, Microbiology & Immunology. 1989, 33(3):269.
  • Sanchiz F, Milla A. A randomized study comparing granulocytecoloy stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy. European Journal of Cancer. 1996, 32A(1):52-56.
  • Schulof RS, Lloyd MJ, Cleary PA, Palasynski SR, Mai DA, Cox Jr JW, Alabaster O, Goldstein AL. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. Journal of Biological Response Modifiers. 1985, 4:147-58.
  • Segatto O, Viora M, Carsetti R, Di Filippo F, Marcelletti C, Natali PG. In vitro modulation of T-cell differentiation antigens on human thymocytes and spleenocytes by a calf thymus acid lysate. Int J Immunother. 1986, 2:301.
  • Shatalova EV, Bel’skii VV, Elinov NP. The comparative characteristics of the effect of immunomodulators on the indices of body nonspecific protection and on the structure of the populations of the causative agents in mixed infections. [Russian] Zhurnal Mikrobiollogii Epidemiologii I Immunobiologii. 1997. Jan-Feb, (1):54-8.
  • Skotnicki AB, Dabrowska-Bernstein BK, Babrowski MP, Gorski A, Czarnecki J, Aleksandrowicz J. Biological properties and clinical use of calf thymus extract TFX-Polfa. In: Goldsten AL (ed), In Thymic Hormones and Lymphokines. Plenum Press, New York. 1984; 545.
  • Skotnicki AB, Hoszowska B, Szerla J, Biedowa E. The effect of calf thymus extract TFX-Polfa on clinical and laboratory parameters in patients with rheumatoid arthritis, in: Abstracts 6th International Congress Immunol. Toronto. 1986; p679.
  • Skotnicki AB. Therapeutic application of calf thymus extract (TFX). Medical Oncology & Tumor Pharmacotherapy. 1989, 6(1):31.
  • Slomkowski M. A trial of treatment with thymus factor (TFX) for chronic autoimmune hemolytic anemias. [Polish] Polski Merkurius Lekarski. 1996 Nov. 1(5):327-8.
  • Smogorzewska EM, Korczynska M, Golebiowska J. The effect of calf thymus extract (TFX) on human T lymphocyte and neutrophil mobility and chemotactic response in vitro. Thymus. 1984, 4:257.
  • Specter S, Lancz G, Hazelden J. Marijuana and immunity: tetrahydrocannibinol-mediated inhibition of lymphocyte blastogenesis. International Journal of Immunopharmacology. 1990, 12(3):261-7.
  • Stankiewiez-Szymezak W, Moszynski B, Dabrowski MP, Dabrowski-Bernzstein BK, Stasiak A. The initial results of TFX-Polfa application in patients with chronic recurrent infections of upper respiratory tract. Pol J Otolaryng. 1986, 2:350.
  • Stanojevic-Bakic N, Vuckovic-Dekic L, Milosevic D, sasic M. Effect of T-activin therapy on indomethacin modulation of lymphoproliferative response in vitro of melanoma patients. Panminerva Medica. 1998 Dec, 40(4):314-8.
  • Stanulis ED, Jordan SD, Rosecrans JA, Holsapple MP. Disruption of Th1/Th2 cytokine balance by cocaine is mediated by corticosterone. Immunopharmacology. 1997 Aug, 37(1):25-33.
  • Stott GH, Wiersma F, Menefee BE, Radwanski FR. Influence of environment on passive immunity in calves. Journal of Dairy Science. 1976 Jul, 59(7):1306-11.
  • Suchkova TN, Sharova NM, Cheknev SB, Suchkov SV. The cyclic nucleotide system of patients with focal scleroderma. Vestnik Dermatologii I Venerologii. 1990, (3):35-8.
  • Suchkova TN, Sharova NM, Suchkov SV. A clinico-immunological assessment of the efficacy of combined methods of treating patients with different immuno-pathological forms of focal scleroderma. Vestnik Dermatologii I Venerologii. 1990, (2):47.
  • T. D. Luckey
    Thymic hormones
    München, Urban & Schwarzenberg, 1973.
  • Tang JL, Lancz G, Specter S, Bullock H. Marijuana and immunity: tetrahydro-cannabinol-mediated inhibition of growth and phagocytic activity of the murine macrophage cell line. International Journal of Immunopharmacology. 1992 Feb, 14(2):253-62/
  • Tas M, Leezenberg JA, Drexhage HA. Beneficial effects of the thymic hormone preparation thymoxtimulin in patients with defects in cell-mediated immunity and chronic purulent rhinosinusitis. A double-blind, cross-over trial on improvements in monocyte polarization and clinical effects. Clinical Experimental Immunology. 1990, 80:304-313.
  • ten Berg RJ, Schellekens PT. Immunosuppressive drugs in clinical medicine [Review] Netherlands Journal of Medicine. 1994 Dec, 45(6):329-38.
  • The German Society for Thymus Therapy
  • The International Association for Organ cell therapy Specialists Switzerland & Germany
  • The Swiss Society for Anti-Ageing Medicine
  • The Thymus in Health and Senescene: Thymus and Immunity
    Nate F. Cardarelli, CRC Press, 1989
  • The Thymus: Regulator of Cellular Immunity (Medical Intelligence Unit)
    John A. Goss, M. Wayne Flye, R. G. Landes, 1993
  • Thymic Peptides in Preclinical and Clinical Medicine – an Update
    H.R. Maurer, A.L. Goldstein, E.D. Hager, Zuckschwerdt Verlag München, Bern, Wien, New York 1997, 182 Pages, ISBN: 3-88603-589-1
  • Tisch M, Heimlich F, Daniel V, Opelz G, Maier H. Cellular immune defect caused by post-surgical radiation therapy in patients with head and neck cancer. Otolaryngology – Head & Neck Surgery. 1998 Oct, 119(4):412-7.
  • Tortora GJ, Funke BR, Case CL. Microbiology, An Introduction, 2nd edition. Benjamin/ Cummings Publishing, Menlo Park, CA 1986.
  • Tortorella C, Ottolenghi A, Moretti AM, Jirillo E, Antonaci S. Thymostimulin administration modulates polymorph metabolic pathway in patients with chronic obstructive pulmonary disease. Immunopharmacology & Immunotoxicology. 1992, 14(3):421.
  • Turowski G, Cybulski L, Politowski M, Turszwili T, Zubel M. First trials of immuno-potentiation by thymic extract (TFX) in surgical patients with malignant disease. Acta Med Pol. 1976,17:18.
  • Twomey JJ, Koutab NM. Selected phenotypic induction of null lymphocytes from mice with thymic and nonthymic agents. Cell Immun. 1982, 72:186.
  • Urban A, Turowski G, Cybulski L. The histological changes of the colon and rectal cancer stroma observed in patients after immunopotentiation by thymus extract (TFX). Patol Pol. 1977, 28:47.
  • Valesini G, Barnaba V, Benvenuto R, Balsano F, Mazzanti P, Cazzola P. A calf thymus lysate improves clinical symptoms and T-cell defects in the early stages of HIV infections: second report. Eur J Cancer Clin Oncol. 1987, 23:1915.
  • Valesini G. A calf thymus lysate improves clinical symptoms and T-cell defects in the early stages of HIV infections: second report. Eur J Clin Oncol. 1987, 23(12):1915.
  • Valesini. Clinical Improvements and partial correction of the T-cell defects of acquired immunodeficiency syndrome (AIDS) and lymphoadenopathy syndrome (LAS) by a calf thymus acid lysate. Eur J Clin Oncol. 1986, 22(4):531.
  • Volozhin AI, Sazhina TG, Chergeshtov IuI, Arion Via, Panin MG, Shipkova TP. The use of tactivin in the combined treatment and prevention of complications in reconstructive operations on the bones of the facial skeleton. [Russian] Stomatologiia. 1996, 75(2):46-8.
  • Vuckovic-Dekic LJ, Susnjar S, Stanojevic-Bakic N, Rajner L, Frim O. The protective activity of Thymex L against radiotherapeutically-induced cellular immuno-depression in lung cancer patients. Neoplasma. 1992, 39(303:171.
  • Vuckovic-Deric L, Stanojevic-Bakic N, Rajner L, Dekic M, Pesic M. Immunomodulation in vitro. The predictive value of in vitro testing of lung cancer patients’ lymphocyte responsiveness to stimulation by Thymex L. A preliminary report. Journal of Experimental & Clinical Cancer Research. 1997 Sep, 16(3):309-12.
  • Wald M, Olejar T, Pouckova P, Zadinova M. Proteinases reduce metastatic dissemination and increase survival time in C57Bl6 mice with the Lewis lung carcinoma. Life Sciences. 1998, 63(17):237-43.
  • Watson ES, Murphy JC, ElSohly HN, ElSohly MA, Turner CE. Effects of administration of coca alkaloids on the primary immune response of mice: interaction with delta 9-tetrahydrocannabinol and ethanol. Toxicology & Applied Pharmacology. 1983 Oct, 71(1):1-13.
  • Weindruch RH, Cheung MK, Verity MA, Walford RI, Modification of mitochondrial respiration by aging and dietary restriction. Mech Ageing Dev. 1980, 12:375-392.
  • Weksler. The senescence of the immune system. Hospital Practice. 1981 Oct, 53-64.
  • Wichmann MW, Ayala A, Chaundry IH. Severe depression of host immune functions following close-bone fracture, soft-tissue trauma, and hemorrhagic shock. Critical Care Medicine. 1998 Aug, 26(8):1372-8.
  • Wiik P, Opstad PK, Botom A. Granulocyte chemiluminescence response to serum oponized zymosan particles ex vivo during long-term strenuous exercise, energy and sleep deprivation in humans. European Journal of Applied Physiology & Occupational Physiology. 1996, 73(3-4):251-8.
  • Wing EJ. Acute starvation in mice reduces the number of T cells and suppresses the development of T-cell-mediated immunity. Immunology. 1988 Apr, 63(4):677-82.
  • Zaporozhchenko VS. Changes in immunity status after surgery on acute pancreatitis with the use of pentoxifylline and low intensity infrared laser irradiation. [Russian] Klinichna Khirurhiia. 1998, (4):4-5.
  • Zeman K, Dworniak D, Tchorzewski H, Pokoca L, Majewska E. Effect of thymic extract on allogeneic MLF and mitogen-induced responses in patients with chronic active hepatitis B. Immunological Investigations. 1991 Dec, 20(7):545.